Replagal Enzyme Replacement Therapy for Children With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 10, 2004

Primary Completion Date

June 15, 2011

Study Completion Date

June 15, 2011

Conditions
Fabry Disease
Interventions
DRUG

Agalsidase alfa

0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks

Trial Locations (14)

10016

NYU School of Medicine, New York

18102

Sacred Heart Hospital, Allentown

20892

Clinical Center, National Institutes of Health, Bethesda

21601

Memorial Hospital, Easton

22556

Office of Michael Cohen, Stafford

33410

Children's Physician Group, Palm Beach Gardens

37916

East Tennessee Children's Hospital, Knoxville

38163

University of Tennessee, Health Science Center, Memphis

63110

St. Louis Children's Hospital, St Louis

70601

Christus St. Patrick Hospital, Lake Charles

75226

Institute of Metabolic Diseases, Dallas

85719

Tucson Access Center of Arizona Kidney Disease Hypertension Center, Tucson

85724

University of Arizona Health Sciences Center, Tucson

M5G 1X8

The Hospital for Sick Children, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY